No-Nonsense Approach to Genetic Kidney Disease in Children
The Research Institute of the 平特五不中 Health Centre鈥檚 (RI-MUHC) push to treat a rare genetic disease in children 鈥� with a higher percentage found in French Canadians 鈥� has received $2 million as part of a led by Genome Canada.
Dr. Paul Goodyer鈥檚 team at the RI-MUHCis at the forefront of North American efforts to develop a novel drug for nephropathic cystinosis, a disorder that is 10 times more prevalent in Qu茅bec. Without treatment, all affected children require kidney transplantation and survival beyond the age of 30 is rare.
鈥淭his is crucial to taking the next steps toward setting up a clinical trial; current treatment is helpful but doesn鈥檛 prevent the eventual outcomes,鈥� says Dr. Goodyer, who is a senior scientist from the Child Health and Human Development Program at the RI-MUHC and a pediatric nephrologist at the Montreal Children鈥檚 Hospital of the MUHC. 鈥淚f successful, this new non-toxic drugwillhave a similar application in a wide variety of genetic diseases caused by Nonsense Mutations, including cancers, while providing significant cost-savings to the Canadian healthcare system.鈥�
This form of nephropathic cystinosis is caused by Nonsense Mutations, an error in the gene code that prematurely signals the cell to stop producing a protein. In cystinosis, the loss of the颁罢狈厂听protein causes a massive build-up of the amino acid cystine in all the cells of the body, which causes gradual organ deterioration.
鈥淥ur drug overcomes Nonsense Mutations by tricking the cell into overlooking the mistake in the code and continuing protein production,鈥� explains Dr. Goodyer, who is also aprofessor of Pediatrics in the Faculty of Medicine at 平特五不中.鈥淏y restoring production of the normal颁罢狈厂听protein, sustained ELX-02 therapy has the potential to be curative.鈥�
Nolan, 9, has been in and out of hospitals since being diagnosed with the disease soon after birth.
鈥淎t six months we realized something wasn鈥檛 right since Nolan was always thirsty and asking for water throughout the night but wasn鈥檛 gaining any weight or showing appetite. He could barely move or do anything that required physical demand. He refused everything. We brought him to the MUHC and straightaway they recognized the typical characteristics of the disease,鈥� says Nolan鈥檚 mother Sophie, who has endured many sleepless nights tending to her son. 鈥淒r. Goodyer鈥檚 research gives us real hope.鈥�
Dr. Goodyer has been collaborating with United States-based Eloxx Pharmaceuticals and expects clinical trials to eventually be concentrated in Montreal alongside Chicago and San Francisco.This project was one of seven to be awarded major funding from a nation-wide Genome Canada Genomic Applications Partnership Program (GAPP), which aims to foster partnerships between academic researchers and end users with projects that translate scientific innovation into action for the benefit of the Canadian population and economy.
"With this funding, local researchers will be capable of developing concrete and effective solutions that will save human lives, thanks to advances in genomics technology.Promising endeavors like Dr. Goodyer鈥檚 project are part of the shift towards precision medicine, which is transforming the way we treat rare diseases such as nephropathic cystinosis,鈥� says Daniel Coderre,President and CEO of G茅nome Qu茅bec.
About the Funding
The Research Institute of the 平特五不中 Health Centre received funds from G茅nome Qu茅bec, which are provided by the minist猫re de l'脡conomie, de la Science et de l'Innovation du Qu茅bec (MESI), the Government of Canada, through Genome Canada, and private partners.
To know more about the research project:聽
About G茅nome Qu茅bec
G茅nome Qu茅bec鈥檚 mission is to catalyze the development and excellence of genomics research and promote its integration and democratization. It is a pillar of the Qu茅bec bioeconomy and contributes to Qu茅bec鈥檚 influence and its social and sustainable development.
The funds invested by G茅nome Qu茅bec are provided by the minist猫re de l'脡conomie, de la Science et de l'Innovation du Qu茅bec (MESI), the Government of Canada, through Genome Canada, and private partners. To learn more, visit聽
About the Research Institute of the MUHC
The Research Institute of the 平特五不中 Health Centre (RI-MUHC) is a world-renowned biomedical and healthcare research centre. The Institute, which is affiliated with the Faculty of Medicine of 平特五不中, is the research arm of the 平特五不中 Health Centre (MUHC) 鈥� an academic health centre located in Montreal, Canada, that has a mandate to focus on complex care within its community. The RI-MUHC supports over 420 researchers and close to 1,200 research trainees devoted to a broad spectrum of fundamental, clinical and health outcomes research at the Glen and the Montreal General Hospital sites of the MUHC. Its research facilities offer a dynamic multidisciplinary environment that fosters collaboration and leverages discovery aimed at improving the health of individual patients across their lifespan. The RI-MUHC is supported in part by the Fonds de recherche du Qu茅bec 鈥� Sant茅 (FRQS).聽
To arrange media interviews with Dr. Goodyer, please contact:
Paul Logothetis
Communications Officer
平特五不中 Health Centre
Tel: 514-210-6376
Paul.Logothetis [at] muhc.mcgill.ca
